|Corporate Fact Sheet|
MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.Learn more
MacroGenics has several positions for full-time employment currently open .Learn more
MacroGenics has developed the Dual-Affinity Re-Targeting (DART) platform technology, which is focused on dual specificity “antibody-like” therapeutic proteins capable of targeting multiple different epitopes with a single recombinant molecule. To date, the company has produced over 100 different DART molecules and has completed in vitro and in vivo proof of concept studies. MacroGenics has established and continues to expand a patent estate around the DART technology.
The DART platform has been specifically engineered to accommodate virtually any variable region sequence in a “plug-and-play” fashion with predictable expression, folding, and antigen recognition. A key technological advancement and distinguishing feature of MacroGenics’ DART is a proprietary covalent linkage which results in a molecule having superior stability, optimal heavy and light chain pairing and predictable antigen recognition. MacroGenics believes that its minimal linker size and content decreases the potential for immunogenicity.
MacroGenics has created several different DART variants for the purposes of extending serum half-life and increasing avidity.
The DART platform is highly flexible and yields an array of product possibilities including, but not limited to: 1) modulation of receptor signaling events, 2) redirected effector cell killing, 3) targeting multiple cytokines or receptor ligands with a single molecule, and 4) targeting multiple epitopes on a pathogen for enhanced neutralization and/or clearance. MacroGenics has developed proof-of-concept data and is developing specific product candidates using this technology. The company has been able to produce DART molecules in both bacterial and mammalian expression systems.
Below are three illustrative DART modalities.